COMMUNIQUÉS West-GlobeNewswire

Medicenna Announces Changes to Board Composition
13/02/2026
TORONTO and HOUSTON, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of [...]
Medicenna Therapeutics Reports Third Quarter Fiscal 2026 Financial Results and Provides a Corporate Update
13/02/2026
Medicenna to present updated internal and external data sets related to bizaxofusp (MDNA55) at the 7th Annual Glioblastoma Development Summit to be held in Boston from 17-19 February 2026 Updated ABILITY-1 clinical data [...]
Nxera Pharma Proposes Changes to its Board of Directors
13/02/2026
Mr. Takeo Morooka nominated for appointment as new External Director Ms. Miwa Seki and Mr. Noriaki Nagai to retire from the Board of Directors Tokyo, Japan and Cambridge, UK, 13 February 2026 – Nxera Pharma Co., Ltd. (“ [...]
EssilorLuxottica announces the launch of a share buyback program
13/02/2026
EssilorLuxottica announces the launch of a share buyback program Paris, France (13 February 2026 – 8:00am) – EssilorLuxottica announces the launch of a share buyback program, reflecting the Group’s confidence in its [...]
Novartis Vanrafia® Phase III data support slowing of kidney function decline in patients with IgA nephropathy
13/02/2026
In ALIGN study, Vanrafia (atrasentan) showed positive difference in eGFR change from baseline vs. placebo at Week 136, 4 weeks after study treatment ended 1 Results favored Vanrafia across multiple timepoints, measures [...]
EssilorLuxottica annonce le lancement d’un programme de rachat d’actions
13/02/2026
EssilorLuxottica annonce le lancement d’un programme de rachat d’actions Paris, France (13 février 2026 – 8h00) – EssilorLuxottica annonce le lancement d’un programme de rachat d’actions qui traduit la confiance du [...]
Nxera Pharma Operational Highlights and Consolidated Results for the Fourth Quarter and Full Year 2025
13/02/2026
Tokyo, Japan and Cambridge, UK, 13 February 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) provides an update on operational activities and reports its consolidated results for the fourth quarter and [...]
Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock
13/02/2026
REDWOOD CITY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (“Coherus” or the “Company”) (NASDAQ: CHRS), today announced the pricing of an underwritten public offering of 28,600,000 shares of the [...]
Tilray élargit son accès aux produits pharmaceutiques au Royaume-Uni grâce à un accord stratégique avec Smartway Pharmaceuticals
13/02/2026
L’accord avec CC Pharma renforce la croissance de Tilray au Royaume-Uni, consolidant sa distribution auprès des pharmacies et des hôpitaux NEW YORK et LONDRES, 13 févr. 2026 (GLOBE NEWSWIRE) -- Tilray Pharma, la [...]
InnoCare Announces First Patient Dosed in the Phase II/III Clinical Trial of Novel TYK2 Inhibitor Soficitinib for Chronic Spontaneous Urticaria in China
13/02/2026
BEIJING, Feb. 12, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first [...]
OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary Shares
13/02/2026
LONDON and NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain ( [...]
Emergent BioSolutions Receives U.S. FDA Approval of Supplemental New Drug Application (sNDA) for NARCAN® Nasal Spray Multipacks
13/02/2026
Approval will broaden the NARCAN ® Nasal Spray portfolio, and improve cost-effectiveness by increasing flexibility and distribution efficiency of this life-saving medication GAITHERSBURG, Md., Feb. 12, 2026 (GLOBE [...]
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2026
13/02/2026
US$82 Million in Pending Proposals Across Multiple Infectious Disease Programs US$40 Million NIAID Funding Award Supports VXV-01 Development Through Phase 1 LIKMEZ® (ATI-1501) Commercial Momentum with Increased U.S. [...]
AVITA Medical Reports Fourth Quarter and Full Year 2025 Financial Results
12/02/2026
VALENCIA, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- AVITA Medical ® , Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions (“AVITA Medical,” or the “Company [...]
Coherus Oncology, Inc. Announces Proposed Public Offering of Common Stock
12/02/2026
REDWOOD CITY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (“Coherus” or the “Company”) (NASDAQ: CHRS), today announced a proposed underwritten public offering of its common stock (the “Offering”). [...]
Cytokinetics to Announce Fourth Quarter Results on February 24, 2026
12/02/2026
SOUTH SAN FRANCISCO, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report fourth quarter results on February 24, 2026 at 4:00 PM Eastern Time [...]
Ultragenyx Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Update
12/02/2026
2025 total revenue of $673 million, Crysvita ® revenue of $481 million and Dojolvi ® revenue of $96 million 2026 total revenue from current products expected to be between $730 million to $760 million Initiated a [...]
Progyny, Inc. Announces Details for Its Fourth Quarter and Full Year 2025 Results Report
12/02/2026
NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, will report its financial results for the quarterly period and full year ended [...]
Celcuity Appoints Charles Romp to its Board of Directors
12/02/2026
MINNEAPOLIS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the appointment of Charles ( [...]

Pages